Salonpas: Uses, Dosage & Side Effects
A medicated topical patch combining methyl salicylate and menthol for temporary relief of mild to moderate muscle and joint pain, available without prescription in most countries
Salonpas is one of the world's most widely used over-the-counter medicated pain relief patches, manufactured by Hisamitsu Pharmaceutical. The standard formulation combines methyl salicylate (10%), a topical salicylate that is converted to salicylic acid after absorption through the skin, with menthol (3%), a cooling counterirritant that activates TRPM8 receptors. Together, these ingredients provide temporary relief of mild to moderate muscle and joint pain associated with backache, arthritis, strains, sprains, and bruises. Salonpas Pain Relieving Patch was the first topical pain reliever to receive U.S. Food and Drug Administration (FDA) New Drug Application approval for over-the-counter marketing in 2008, and it is sold in more than 40 countries globally.
Quick Facts: Salonpas
Key Takeaways
- Salonpas is an over-the-counter medicated patch that delivers methyl salicylate (10%) and menthol (3%) transdermally for temporary relief of mild to moderate muscle and joint pain from backache, arthritis, strains, sprains, and bruises.
- Apply no more than one patch to the affected area at a time for up to 8 hours, and do not exceed 3 patches per day. Discontinue if skin irritation develops and consult a doctor if pain persists longer than 7 days.
- Do not use Salonpas on broken or irritated skin, under occlusive dressings, with heating pads, or on children under 12 without medical advice. Avoid contact with eyes, mouth, and genital areas.
- People taking warfarin or other anticoagulants should consult a healthcare professional before use, as percutaneous salicylate absorption can increase INR and bleeding risk in rare cases.
- Salonpas should be avoided during the third trimester of pregnancy and used only under medical supervision during the first two trimesters or while breastfeeding, as methyl salicylate can be absorbed and reach the fetus or breast milk.
What Is Salonpas and What Is It Used For?
Salonpas is a topical analgesic patch developed by the Japanese pharmaceutical company Hisamitsu Pharmaceutical Co., Inc., with a product heritage dating back more than a century. The modern Salonpas formulation combines two complementary pain-relieving ingredients — methyl salicylate, a salicylate class topical analgesic, and menthol, a counterirritant derived naturally from mint oils or produced synthetically. Together, they are delivered through a flexible adhesive patch that maintains close skin contact over the painful area for several hours at a time.
The product achieved a significant regulatory milestone in January 2008, when the U.S. Food and Drug Administration (FDA) approved Salonpas Pain Relieving Patch under a New Drug Application (NDA 21-929), making it the first over-the-counter topical pain reliever patch to gain FDA approval through the rigorous NDA pathway rather than being marketed under a general OTC monograph. This approval required Hisamitsu to provide clinical trial evidence of both efficacy and safety, which set Salonpas apart from many generic salicylate-menthol products available at the time. The patch is now sold in more than 40 countries and is one of the best-selling OTC pain relief brands globally.
Salonpas is indicated for the temporary relief of mild to moderate muscle and joint pain associated with several common musculoskeletal complaints. According to the FDA-approved drug label, these include: simple backache; arthritis pain (particularly mild osteoarthritis affecting superficial joints such as the knees, elbows, wrists, and ankles); muscle strains from physical activity or overuse; sprains following minor soft tissue injuries; and bruises. In addition, patients commonly use Salonpas for neck and shoulder pain, tension-related muscle stiffness, and post-exercise soreness (delayed-onset muscle soreness, or DOMS).
The mechanism of action of Salonpas reflects the combined effects of its two active ingredients, each of which works through a distinct pharmacological pathway. Methyl salicylate is a salicylic acid ester that penetrates the skin barrier and is hydrolyzed by tissue esterases to release salicylic acid in the underlying muscle and connective tissue. Salicylic acid inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing the local synthesis of prostaglandins that sensitize pain receptors and contribute to inflammation. This produces a localized analgesic and mild anti-inflammatory effect at the site of application, with significantly less systemic exposure than occurs with oral salicylates such as aspirin.
Menthol complements this action through a distinctly different mechanism. It is a selective agonist of the transient receptor potential melastatin 8 (TRPM8) channel, a cold-sensing receptor found on sensory nerve endings in the skin. When menthol activates TRPM8, it produces the characteristic cooling sensation that users feel shortly after applying the patch. This cooling effect acts as a counterirritant, modulating the perception of deeper pain signals according to the gate-control theory of pain. Clinical pharmacology studies suggest that menthol may also exert mild analgesic effects through activation of kappa-opioid receptors and modulation of sodium-channel activity in nociceptive nerve fibers, although the cooling counterirritant action is considered the primary contributor to perceived pain relief.
Salonpas is available in several formulations to suit different preferences and clinical needs. The classic Salonpas Pain Relieving Patch is the smallest format, roughly 6.5 by 4.2 centimetres, and is ideal for focal pain over small areas such as the wrist, neck, or elbow. The Salonpas Pain Relief Patch Large measures approximately 10 by 14 centimetres, designed for larger surfaces such as the lower back or thigh. Salonpas Gel-Patch uses a hydrogel adhesive with higher menthol content (typically 5.7% menthol and 6.3% methyl salicylate) for a more pronounced cooling sensation. Salonpas Gel-Patch HOT adds capsicum extract to generate a warming sensation through TRPV1 receptor activation, preferred by some users for chronic muscular tension. Liquid formulations such as Salonpas Deep Relieving Gel and Salonpas JET Spray are available for people who prefer rub-on or spray-on products to adhesive patches.
Clinical evidence supporting Salonpas includes several randomized controlled trials evaluating methyl salicylate/menthol patches for musculoskeletal pain. A pivotal multicenter double-blind trial submitted to the FDA showed statistically significant reductions in pain intensity compared to placebo patches in adults with acute muscle strain, and a 2017 Cochrane overview of topical analgesics concluded that salicylate-containing rubefacients can provide meaningful short-term pain relief in acute musculoskeletal injuries, although the quality of individual studies varies. Topical delivery has the advantage of localized action with substantially reduced systemic exposure compared to oral NSAIDs or salicylates, particularly important for older adults and patients with gastrointestinal, renal, or cardiovascular risk factors.
What Should You Know Before Using Salonpas?
Before using Salonpas, it is important to understand the specific situations in which it should be avoided or used only with medical guidance. Although the medication is available without prescription and is considered generally safe for short-term use on small body areas, certain patient groups and clinical circumstances require careful consideration. Always read the product packaging and consult a pharmacist or healthcare provider if you are uncertain whether Salonpas is appropriate for you.
Contraindications
There are several situations in which Salonpas must not be used. These represent absolute contraindications where the potential risks outweigh the modest benefits of short-term pain relief. You should not use Salonpas if you:
- Are allergic to methyl salicylate, menthol, salicylates, aspirin, or other non-steroidal anti-inflammatory drugs (NSAIDs). Cross-reactivity between salicylates and other NSAIDs can trigger hypersensitivity reactions including hives (urticaria), bronchospasm, angioedema, and in rare cases anaphylaxis. Patients with a history of aspirin-exacerbated respiratory disease (AERD, also known as Samter's triad — asthma, nasal polyps, and aspirin sensitivity) are at particular risk.
- Have known allergies to any of the inactive ingredients such as the adhesive components, colophony (rosin derivatives) used in some adhesive formulations, or fragrance compounds.
- Have open wounds, cuts, abrasions, burns, or actively inflamed or infected skin at the intended application site. Damaged skin dramatically increases percutaneous absorption, raising the risk of systemic salicylate exposure and tissue irritation.
- Are in the last three months (third trimester) of pregnancy. Salicylates, including topical methyl salicylate, can inhibit prostaglandin synthesis in the fetus and potentially cause premature closure of the ductus arteriosus, prolonged labor, and increased bleeding in mother and baby.
- Are under 12 years of age (self-medication without medical advice). Children, especially young children, are at higher risk of systemic salicylate toxicity because of a higher ratio of skin surface area to body weight, and salicylates have been associated with Reye's syndrome in children and adolescents recovering from viral infections.
Additionally, the patch must not be applied to certain body areas regardless of overall health status:
- On or near the eyes, eyelids, mouth, nose, or genital mucosa. The active ingredients can cause severe irritation or chemical injury to mucous membranes.
- On the face generally, unless specifically directed by a healthcare professional.
- Over large areas of the body simultaneously. Multiple patches covering extensive body surface area can lead to clinically significant systemic salicylate absorption.
- On skin with a rash, eczema, psoriasis, or other dermatological condition unless a dermatologist has advised that use is safe.
Warnings and Precautions
Although topical methyl salicylate is intended for local effect, meaningful amounts can be absorbed through the skin, especially when patches are applied to large areas, used for extended periods, placed on damaged skin, or combined with occlusive coverings or heat. Cases of systemic salicylate toxicity and, in rare instances, fatalities have been reported in individuals using excessive amounts of topical salicylate products. Use only as directed.
Consult your doctor or pharmacist before using Salonpas if you have any of the following conditions or risk factors:
- Asthma or aspirin-exacerbated respiratory disease: All salicylates and NSAIDs can trigger bronchospasm, nasal polyp exacerbation, and severe respiratory reactions in susceptible individuals. Even topical exposure has rarely been reported to cause reactions in highly sensitive patients.
- Kidney disease or reduced renal function: Salicylates depend on renal elimination, and impaired kidney function can prolong their systemic effects. Older adults and patients with chronic kidney disease should use the minimum effective amount for the shortest duration necessary.
- Liver disease: The liver plays a role in salicylate metabolism; significant hepatic impairment can increase salicylate exposure and the risk of adverse effects.
- Bleeding disorders or active bleeding: Salicylates can inhibit platelet aggregation, even at the relatively low systemic levels achieved with topical application. Patients with bleeding diatheses, upcoming surgery, or active gastrointestinal ulceration should discuss appropriate pain management alternatives with a healthcare provider.
- Diabetes with peripheral neuropathy: Reduced skin sensation can delay recognition of skin irritation, burns, or contact dermatitis caused by the patch. Inspect the application site regularly.
- History of contact dermatitis or sensitive skin: The adhesive and active ingredients can cause irritant or allergic contact dermatitis. A test application on a small area of skin for 24 hours before routine use may be advisable.
When using Salonpas, observe the following general precautions to minimize the risk of adverse effects. Do not combine the patch with external heat sources such as heating pads, hot water bottles, electric blankets, saunas, or prolonged sun exposure, as heat increases both skin permeability and the risk of thermal injury. Do not apply occlusive dressings (plastic wraps, airtight bandages, or tight elastic bandages) over the patch, because occlusion increases systemic absorption significantly and can provoke skin irritation or chemical burns. Wash your hands thoroughly after applying or removing the patch to avoid transferring the active ingredients to your eyes, mouth, or other sensitive areas.
Salonpas is intended for short-term, symptomatic pain relief. If pain persists or worsens after 7 days of use, if symptoms recur after a few days of improvement, or if you experience skin irritation that does not resolve within 24 hours of removing the patch, stop using the product and consult a healthcare professional. Chronic pain lasting longer than a few weeks should be evaluated by a doctor rather than managed solely with OTC topical analgesics.
Pregnancy and Breastfeeding
Salonpas should not be used during the third trimester of pregnancy (the last three months). Like all salicylates and NSAIDs, topical methyl salicylate can reduce prostaglandin synthesis in the fetus, potentially causing premature closure of the ductus arteriosus — a critical blood vessel that must remain open until after birth. Late-pregnancy use of salicylates has also been associated with prolonged labor, reduced amniotic fluid volume (oligohydramnios), and increased risk of bleeding in both mother and newborn.
During the first and second trimesters, Salonpas should only be used when clearly needed and on the advice of a healthcare provider, at the smallest effective dose for the shortest possible duration. Although topical application results in much lower systemic salicylate exposure than oral aspirin, methyl salicylate is absorbed through the skin and can cross the placenta. Alternative pain management strategies, including physical therapy, heat or ice (appropriately used), and paracetamol (acetaminophen) at standard doses, are generally preferred during pregnancy.
For breastfeeding mothers, small amounts of salicylate can pass into breast milk following topical application of methyl salicylate, although systemic concentrations are typically low with patch use over a limited area. If Salonpas is used during breastfeeding, do not apply the patch to the breast or anywhere the infant's skin or mouth could come into direct contact with the treated area. Consult a healthcare professional about the relative safety of topical salicylates during lactation, especially in the early weeks after delivery when the newborn is most susceptible to pharmacologic effects.
Use in Children and Adolescents
The FDA-approved label specifies that Salonpas Pain Relieving Patch should not be used in children under 12 years of age without medical advice. Children are at higher risk of systemic salicylate absorption because their skin is thinner and more permeable, and their body surface area is larger relative to their mass. Several case reports have documented serious — and in extreme cases fatal — methyl salicylate toxicity in children who ingested topical salicylate products or had multiple patches applied over large body areas.
Additionally, oral salicylates have been epidemiologically associated with Reye's syndrome, a rare but potentially fatal condition characterized by acute encephalopathy and hepatic dysfunction in children and adolescents recovering from viral infections such as influenza and chickenpox. Although Reye's syndrome has not been definitively linked to topical methyl salicylate, the general medical consensus is to avoid all salicylate products in children with active or recent viral illness. Pediatricians can advise on safer alternatives for children with muscle or joint pain.
Driving and Operating Machinery
Salonpas has no known effects on the ability to drive or operate machinery when used as directed. The strong menthol sensation may be distracting immediately after application, but this is not associated with impaired cognition or motor function. If you experience dizziness, drowsiness, or other systemic symptoms — all of which should be rare with topical use — avoid driving and seek medical advice.
How Does Salonpas Interact with Other Drugs?
Most topical products used as directed produce very limited systemic drug exposure, and for Salonpas applied over a small area for a few hours at a time, clinically important drug interactions are uncommon. However, the product is often used over prolonged periods, over larger surface areas, or in combination with oral medications that share the same pharmacologic targets. In these circumstances, the percutaneous absorption of methyl salicylate — and its hydrolysis to salicylic acid — can produce measurable systemic effects relevant to several drug classes.
Always inform your doctor, pharmacist, or other healthcare provider about all prescription medications, over-the-counter products, vitamins, herbal supplements, and topical products you are using. Bring a current list of medications with you to medical appointments. The following interactions are the most clinically relevant and should be considered before starting Salonpas.
Major Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Warfarin and other coumarin anticoagulants | Published case reports and pharmacokinetic studies document elevated INR and bleeding events after extensive or prolonged use of topical methyl salicylate products in patients on warfarin; absorbed salicylate can displace warfarin from plasma proteins and inhibit platelet function | Avoid routine use in warfarin-treated patients without medical supervision. Monitor INR closely if used. Seek immediate medical attention for unusual bruising, bleeding gums, nosebleeds, blood in urine or stool, or prolonged bleeding from cuts. |
| Oral aspirin and other salicylates | Additive salicylate exposure; concurrent use can raise the total systemic salicylate load and increase risk of gastrointestinal irritation, tinnitus, and in rare cases salicylism (salicylate toxicity) | Avoid combining Salonpas with high-dose aspirin. Low-dose (75–100 mg) aspirin for cardiovascular prevention is generally considered low-risk with occasional Salonpas use, but discuss with a doctor if using daily long-term. |
| Oral NSAIDs (ibuprofen, naproxen, diclofenac) | Although pharmacologically similar mechanisms of action, clinical interactions from co-use of a topical salicylate patch and oral NSAIDs are generally minor; however, combined use increases gastrointestinal and renal risk | Generally safe for short-term use but avoid combining for prolonged periods. Do not stack multiple topical NSAID/salicylate products on the same skin area. |
| Methotrexate | Salicylates can reduce renal clearance of methotrexate and displace it from plasma proteins, potentially increasing methotrexate concentrations to toxic levels | Caution advised, particularly with high-dose methotrexate regimens in oncology or rheumatology. Consult the treating specialist before regular use of topical salicylates. |
| Heparin and direct oral anticoagulants (DOACs) | Potential additive bleeding risk with absorbed salicylate, particularly with extensive or occluded topical application | Use only after discussion with the prescriber. Monitor for signs of abnormal bleeding. Choose paracetamol-based or non-pharmacologic options where possible. |
Minor Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Other topical salicylates or menthol products | Applying multiple salicylate- or menthol-containing topical products (rubs, balms, patches) to the same area can cause additive skin irritation and unpredictably increase systemic exposure | Use only one topical analgesic product at a time on a given body area. Allow at least 24 hours between switching products on the same skin area. |
| Oral corticosteroids (prednisolone, dexamethasone) | Chronic corticosteroid use increases gastrointestinal and bleeding risk; concurrent salicylate exposure could theoretically compound this risk | Short-term Salonpas use at labeled doses is generally acceptable but avoid long-term co-use. Consider gastroprotection if oral salicylates are also required. |
| Oral hypoglycemic agents (sulfonylureas) | High systemic salicylate exposure has been reported to enhance the hypoglycemic effect of sulfonylureas | Monitor blood glucose with extensive or prolonged Salonpas use in people with diabetes. |
| ACE inhibitors, ARBs, and diuretics | High doses of systemic salicylates can reduce the antihypertensive effect of these agents and increase the risk of acute kidney injury, although clinically relevant effects with topical Salonpas use are uncommon | Maintain adequate hydration and monitor blood pressure. Prolonged use warrants review with the prescriber. |
| Alcohol (topical application area) | Do not apply alcohol-based products or consume large quantities of alcohol just before applying Salonpas, as alcohol can increase skin permeability | Allow the skin to dry fully before applying the patch; avoid applying on areas cleaned with strong alcohol solutions. |
Do not apply Salonpas on top of other topical medications (such as corticosteroid creams, topical NSAID gels, or counterirritant rubs) at the same site. This can unpredictably change absorption of both products, potentially producing either reduced efficacy or increased adverse effects. Allow previous topical products to be washed off before applying the patch.
What Is the Correct Dosage of Salonpas?
Correct dosing of Salonpas is largely a matter of application technique, duration, and frequency. The product is not dosed by weight or titrated like many oral medications; instead, a single patch (or less, if cut to size with the protective film still on) is applied to the area of pain for a limited duration, with strict upper limits on the number of patches per day and the total duration of self-treatment. The following guidance applies to the standard Salonpas Pain Relieving Patch and closely related formulations; always follow the specific instructions on the packaging of the product you are using, as formulations and recommended durations vary.
Adults and Children 12 Years and Older
Standard Pain Relieving Patch (Methyl Salicylate 10% / Menthol 3%)
Single application: Apply 1 patch to the affected area.
Wear time: Up to 8 hours per patch.
Maximum frequency: No more than 3 patches per day.
Maximum duration: Do not use for more than 3 consecutive days without medical advice.
Reapplication: Wait at least 1 hour between removing one patch and applying another to the same area. Do not apply to the same spot continuously.
Step-by-Step Application Method
Correct application is essential for both safety and effectiveness. Follow these steps for each patch:
- Clean the skin: Wash the affected area with soap and water, then dry thoroughly. The patch will not adhere well to damp, oily, or dirty skin.
- Inspect the skin: Verify there are no cuts, abrasions, rashes, or irritated skin at the application site. If any are present, choose a different location or do not use the product.
- Open the pouch: Each patch is typically sealed in a resealable foil pouch to preserve potency. Remove one patch, then reseal the pouch to protect remaining patches from light and air.
- Remove the backing film: Peel off the transparent protective film to expose the adhesive side of the patch. Avoid touching the adhesive surface as much as possible.
- Apply to the skin: Place the adhesive side on the painful area and smooth it down firmly to ensure even contact. Avoid creasing or folding the patch.
- Wash your hands: Immediately wash hands with soap and water after handling the patch. Do not touch your eyes, mouth, nose, or genital area until hands are thoroughly clean.
- Wear time: Leave the patch in place for up to 8 hours. Remove gently by lifting one corner and peeling slowly. If adhesive remains, it can be wiped off with oil or warm water and soap.
- Dispose properly: Fold the used patch in half with the adhesive sides together, and dispose of it in a trash receptacle out of reach of children and pets.
Salonpas Gel-Patch and Gel-Patch HOT
Gel-Patch Formulations (Methyl Salicylate ~6.3% / Menthol ~5.7%, with optional capsicum in HOT)
Single application: Apply 1 gel-patch to the affected area.
Wear time: Up to 8 to 12 hours per patch depending on the specific product.
Maximum frequency: Up to 2 patches per day.
Special notes: The HOT variant with capsicum extract should not be used on sensitive skin, in combination with heat, or immediately before or after showering.
Reapplication: Allow the skin to rest for at least several hours between patches on the same site.
Salonpas Deep Relieving Gel and Liquid Formulations
Topical Gel / Cream (Methyl Salicylate + Menthol)
Single application: Apply a thin layer (approximately pea-sized to walnut-sized amount, depending on area) to the affected area.
Frequency: Up to 3 to 4 times daily.
Method: Rub gently into the skin until fully absorbed. Wash hands thoroughly after use.
Duration: For short-term use; if symptoms persist beyond 7 days, consult a healthcare professional.
Children Under 12 Years
Salonpas products are not recommended for children under 12 years of age without specific medical advice. Parents and caregivers should consult a pediatrician or pharmacist before using any topical salicylate product in younger children. Safer pain-relief alternatives for mild musculoskeletal pain in children include weight-based paracetamol (acetaminophen), ibuprofen syrup (in children over 3 months), physical therapy, ice or heat application (with appropriate precautions), and rest.
Elderly Patients (65 Years and Older)
No specific dose adjustment is required for older adults using Salonpas at the recommended dose and duration. However, older adults may have thinner skin, reduced fat padding, and co-existing conditions such as renal impairment, cardiovascular disease, or concurrent anticoagulant therapy that modify the benefit-risk balance. Older adults should start with short wear times (for example, 4 to 6 hours initially) to assess skin tolerance, inspect the application site regularly for irritation, and involve a pharmacist or doctor in decisions about regular use beyond occasional symptomatic relief.
Hepatic and Renal Impairment
For patients with mild to moderate liver or kidney impairment, no formal dose adjustment is specified for topical use as directed. However, reduced organ function can prolong salicylate elimination if systemic absorption occurs, so these patients should use the minimum number of patches for the shortest effective duration and should not exceed the maximum daily dose. Patients with severe liver or kidney disease should consult a healthcare professional before using topical salicylate products.
Missed Dose
Because Salonpas is used as needed for symptomatic relief, there is no concept of a strict "missed dose." If you had planned to apply a patch and forgot, you can apply it when you remember, as long as you do not exceed the maximum number of patches per day or the recommended wear time. Do not apply two patches simultaneously to the same area to compensate for a forgotten application.
Overdose and Accidental Ingestion
Accidental ingestion of methyl salicylate — especially concentrated liquid or gel forms, or multiple patches — is a medical emergency, particularly in children. As little as 5 mL of concentrated methyl salicylate (oil of wintergreen) can be fatal in a small child. If ingestion is suspected, call your local poison control center or emergency services immediately, even in the absence of symptoms.
Overdose from correctly used single Salonpas patches is extremely rare because systemic absorption from one small patch over several hours is limited. However, overdose from topical methyl salicylate products has occurred in the following scenarios: applying many patches simultaneously over large body areas; covering patches with occlusive dressings or heat; using patches for durations far exceeding labeled recommendations; and — most seriously — oral ingestion, particularly of concentrated liquid preparations.
Symptoms of salicylate toxicity (salicylism) include: tinnitus (ringing in the ears), nausea and vomiting, hyperventilation or rapid breathing, confusion, dizziness, and sweating. Severe overdose can progress to respiratory alkalosis followed by metabolic acidosis, hypoglycemia, seizures, coma, and death. Treatment is supportive and may include gastric decontamination if ingestion was recent, intravenous fluids, urinary alkalinization with bicarbonate, and in severe cases hemodialysis. There is no specific antidote for salicylate overdose.
What Are the Side Effects of Salonpas?
Because Salonpas is applied to the skin and only a small fraction of the active ingredients is typically absorbed systemically, the adverse-effect profile is dominated by local skin reactions. Systemic effects similar to those of oral salicylates remain possible, however, particularly with misuse, sensitive patients, or very extensive application. The following classification summarizes reactions reported in clinical trials, post-marketing surveillance, and case reports, with frequency categories aligned with conventional medical definitions.
Severe skin rash with blisters or peeling; swelling of the face, lips, tongue or throat; difficulty breathing, wheezing, or severe chest tightness; sudden severe dizziness or faintness; rapid breathing with confusion, ringing in the ears, or persistent vomiting. These could indicate a serious allergic reaction or systemic salicylate toxicity requiring emergency care.
Common
- Skin redness (erythema): Pink or red discoloration at or near the application site, usually resolving within a few hours of patch removal
- Mild warming or cooling sensation: A burning, tingling, or cooling feeling — particularly with menthol and HOT variants — which is part of the intended counterirritant effect but can be uncomfortable in some people
- Itching (pruritus): Localized itching on or around the treated skin
- Mild contact dermatitis: Inflammation of the skin beneath the patch, often due to the adhesive or active ingredients
Uncommon
- Dry skin or peeling: Flaking or scaling at the application area after repeated use
- Mild swelling or edema: Localized swelling at the treated site
- Hyperpigmentation: Temporary darkening of the skin, more common in people with darker skin tones
- Worsened pain or tenderness: Paradoxical increase in local discomfort in some individuals
Rare
- Allergic contact dermatitis: Delayed hypersensitivity reaction with intense redness, swelling, and itching, sometimes with blistering
- Chemical burns: First- or second-degree burns under the patch, especially with prolonged wear or occlusion
- Urticaria (hives): Widespread itchy, raised wheals beyond the application area
- Photosensitivity: Exaggerated sunburn-like response on treated skin exposed to UV light
Very Rare
- Severe cutaneous reactions: Stevens-Johnson syndrome and erythema multiforme have been reported with salicylate products in isolated cases
- Bronchospasm (asthma attack): In individuals with aspirin-sensitive asthma, topical salicylate exposure can rarely trigger a respiratory reaction
- Angioedema: Swelling of the face, lips, tongue, or throat requiring immediate medical evaluation
- Anaphylaxis: Severe systemic allergic reaction with hypotension and respiratory compromise
- Salicylate toxicity (salicylism): With misuse or extensive prolonged application — tinnitus, vertigo, nausea, hyperventilation, and in extreme cases metabolic disturbance, seizures, or death
- INR elevation and bleeding: In patients taking warfarin, rare case reports describe clinically significant INR rise and bleeding after prolonged extensive use of topical salicylates
In clinical use, the overwhelming majority of side effects are local skin reactions rather than systemic. Many mild reactions resolve on their own within 24 hours of removing the patch. If redness or itching persists longer than 24 hours, if blistering or severe pain develops, or if the skin appears burned, discontinue use and contact a healthcare professional.
Some factors increase the risk of local reactions and should be considered when using Salonpas. These include: applying the patch to highly sensitive skin areas (inner arms, neck, inner thighs); failing to remove the patch on time; applying the same patch or new patches to the same spot repeatedly; concurrent use of other topical products on the same area; exposure of the treated skin to sunlight, UV tanning beds, heating pads, hot water, or saunas; and pre-existing skin conditions such as atopic dermatitis or psoriasis.
If you experience any unexpected symptoms while using Salonpas — even symptoms not listed here — discontinue use and consult a healthcare professional. You can also report suspected side effects to your national pharmacovigilance authority (for example, the U.S. FDA MedWatch program, the UK MHRA Yellow Card scheme, Health Canada's MedEffect program, or the European Medicines Agency's EudraVigilance system). Reporting adverse events helps authorities monitor medication safety and update guidance when needed.
How Should You Store Salonpas?
Proper storage of Salonpas helps preserve both the potency of the active ingredients and the adhesive quality of the patches. The following storage practices apply to most Salonpas products, though specific guidance on the individual package should always take precedence if different.
- Temperature: Store at controlled room temperature, typically between 15°C and 30°C (59°F to 86°F). Avoid exposure to high temperatures such as in a hot car, on a radiator, or in direct sunlight, which can degrade the menthol and affect the adhesive.
- Humidity: Avoid high-humidity environments such as bathrooms or damp storage areas, which can reduce adhesive strength. Store in a dry area such as a bedroom drawer or kitchen cabinet away from the stove and sink.
- Light: Protect from direct sunlight and strong artificial light by keeping patches in their original foil pouch. Exposure to light can reduce the stability of methyl salicylate over time.
- Packaging: Keep patches in the original sealed foil pouch until ready to use, and reseal the pouch tightly after each use if it contains multiple patches. Air exposure can cause menthol to volatilize and reduce product effectiveness.
- Child and pet safety: Keep all Salonpas products out of the sight and reach of children and pets. Even used patches retain residual active ingredients and can cause harm if chewed or ingested. Methyl salicylate is particularly toxic to cats, dogs, and young children.
- Expiry date: Do not use Salonpas after the expiry date printed on the packaging (typically shown as "EXP" followed by a month and year). The expiry date refers to the last day of the month shown. Expired patches may have reduced potency and altered adhesive quality.
- Disposal: Fold used patches in half with the adhesive sides together before disposal to prevent accidental skin contact or ingestion. Dispose of used and unused expired patches in household waste, ideally in a container children and pets cannot access, or return unused products to a pharmacy for safe disposal in regions with medication take-back programs.
Liquid formulations (gels and sprays) have additional storage considerations. Keep the cap tightly closed between uses to prevent evaporation of alcohol and menthol. Do not transfer contents to unlabeled containers, which could lead to accidental ingestion. Sprays should be protected from extreme temperatures, as pressurized containers can rupture in heat or direct sunlight.
What Does Salonpas Contain?
Salonpas products share a common active-ingredient backbone of methyl salicylate and menthol but vary in concentrations, additional active ingredients, and inactive components depending on the specific formulation. Understanding the composition helps identify potential allergens and make informed choices between the standard patch, gel-patch, HOT variant, and liquid products.
Standard Salonpas Pain Relieving Patch
Active ingredients (per patch):
- Methyl salicylate 10% (w/w) — the principal topical analgesic/anti-inflammatory component, hydrolyzed to salicylic acid after skin absorption
- Menthol 3% (w/w) — counterirritant cooling agent acting on TRPM8 receptors
Typical inactive ingredients: Alicyclic saturated hydrocarbon resin (tackifier), BHT (butylated hydroxytoluene, antioxidant), D&C yellow #10 (coloring in some variants), FD&C blue #1, glyceryl rosinate, polyisobutylene (adhesive base), polybutene, sorbitan sesquioleate (emulsifier), styrene-isoprene-styrene block copolymer (SIS adhesive), and a polyester backing film. The exact excipient profile varies between manufacturing sites and international markets.
Some adhesive components — particularly colophony-derived rosin esters (glyceryl rosinate) and the styrene-isoprene-styrene elastomer — are recognized causes of allergic contact dermatitis. Individuals with known allergies to adhesive tape, colophony, or rubber accelerators should use Salonpas with caution and discontinue at the first sign of rash. Fragrance and menthol themselves can also provoke contact allergy in susceptible patients.
Salonpas Gel-Patch and Gel-Patch HOT
Active ingredients (typical):
- Methyl salicylate approximately 6.3%
- L-menthol approximately 5.7%
- Capsicum extract (HOT variant only): Standardized preparation of capsaicinoids providing a warming sensation through TRPV1 activation
- Additional analgesic or anti-inflammatory co-ingredients (in some international versions): Tocopherol acetate (vitamin E acetate), dl-camphor, glycol salicylate, thymol
Typical inactive ingredients: Purified water, hydrogel matrix (water-based adhesive gel containing cellulose derivatives and glycerin), polyacrylate adhesives, titanium dioxide (for appearance), aluminum glycinate, edetate sodium, kaolin, and polyester or non-woven backing. Hydrogel patches tend to be more comfortable in warmer climates because their water content provides additional cooling, but they may be less durable over 8+ hour wear times than the traditional rubber-based adhesive.
Salonpas Deep Relieving Gel and Related Liquid Products
Active ingredients (typical):
- Methyl salicylate typically 10% to 15%
- Menthol typically 3% to 8%
- Camphor in some formulations (approximately 3% to 5%)
Typical inactive ingredients: Isopropyl alcohol, ethanol, water, carbomer (thickener), triethanolamine (pH adjuster), fragrance, and preservatives such as phenoxyethanol. Alcohol-based formulations dry quickly on the skin but can cause stinging on broken skin and should be kept away from eyes, mucous membranes, and open flames.
Appearance and Packaging
The classic Salonpas Pain Relieving Patch is a thin, flexible, beige-colored fabric patch measuring approximately 6.5 × 4.2 cm. It is sealed in an individual foil pouch, with multiple patches per retail carton (typically 20, 40, or 60 patches). Larger formats such as the Salonpas Pain Relief Patch Large measure approximately 10 × 14 cm. Gel-patches are similar in appearance but have a clear or translucent hydrogel layer visible through the backing. Always check the packaging for manufacture and expiry dates, lot number, and the complete ingredient list before use.
If you have known allergies to any component of Salonpas, or if you develop a reaction during use, always retain the packaging to share with your healthcare provider. The full ingredient list printed on the carton is the most reliable reference for specific excipients, which can change between batches and international markets.
Frequently Asked Questions About Salonpas
Yes, Salonpas is available over the counter without a prescription in virtually all markets where it is sold, including the United States, United Kingdom, European Union countries, Canada, Australia, Japan, and across Asia. In January 2008, the U.S. Food and Drug Administration approved Salonpas Pain Relieving Patch as the first over-the-counter topical pain reliever patch to gain FDA approval under a New Drug Application (NDA 21-929), confirming its safety and efficacy for non-prescription use. You can typically find it in the pain-relief or first-aid aisle of pharmacies, supermarkets, and drugstores. Regulations vary slightly between countries, so always check local labeling and consult a pharmacist if you are unsure about any aspect of use.
Salonpas is used for the temporary relief of mild to moderate muscle and joint pain associated with several common conditions. According to its FDA-approved indications, these include simple backache, arthritis pain (particularly mild osteoarthritis in superficial joints), muscle strains, sprains, and bruises. In addition to these labeled uses, people commonly apply Salonpas for neck and shoulder pain, tension-related muscle stiffness, mild repetitive-strain discomfort, and post-exercise muscle soreness. Salonpas is intended for short-term, symptomatic relief; chronic or severe pain should be evaluated and managed by a healthcare professional rather than treated solely with over-the-counter topical products.
The standard Salonpas Pain Relieving Patch should be worn for up to 8 hours at a time, after which it should be removed. The labeled maximum is 3 patches per day, and self-treatment should not continue for more than 3 consecutive days without consulting a healthcare professional. Exceeding these limits — for example, wearing the patch overnight beyond 8 hours, stacking multiple patches, or using them continuously for weeks — significantly increases the risk of skin irritation, chemical burns, and rare systemic salicylate toxicity. Gel-patch formulations may have different wear times (up to 12 hours in some markets); always follow the specific instructions on the product you are using.
You should consult your doctor or pharmacist before using Salonpas if you are taking warfarin, heparin, or direct oral anticoagulants such as apixaban, rivaroxaban, or dabigatran. Methyl salicylate is absorbed through the skin and is converted to salicylic acid, which can displace warfarin from plasma proteins, inhibit platelet aggregation, and modestly enhance the anticoagulant effect. Several published case reports describe elevated INR and bleeding events in warfarin-treated patients who used topical methyl salicylate products extensively or for prolonged periods. For most patients on oral anticoagulants, safer alternatives for mild musculoskeletal pain include paracetamol (acetaminophen) and non-pharmacologic approaches such as physical therapy, heat or cold therapy, and rest.
Salonpas should not be used in children under 12 years of age without specific medical advice. Children are at increased risk of systemic salicylate absorption because of their higher skin-surface-area-to-body-weight ratio, and salicylates have been epidemiologically linked to Reye's syndrome in children and adolescents recovering from viral infections such as influenza or chickenpox. Several tragic case reports have documented fatal methyl salicylate toxicity in young children who either ingested topical salicylate products or had excessive quantities applied to their skin. For children with mild muscle or joint pain, safer options include weight-based paracetamol (acetaminophen), pediatric-formulated ibuprofen, physical therapy, and appropriate ice or heat therapy under parental supervision. Always consult a pediatrician for persistent pain in children.
Salonpas is not recommended during the last three months (third trimester) of pregnancy. Like all salicylates and NSAIDs, topical methyl salicylate can inhibit prostaglandin synthesis, potentially causing premature closure of the fetal ductus arteriosus, reduced fetal kidney function leading to oligohydramnios, prolonged labor, and increased bleeding risk for mother and baby. During the first and second trimesters, Salonpas should only be used if clearly needed and under the advice of a healthcare professional, at the smallest effective amount for the shortest duration. Paracetamol (acetaminophen) is generally considered a safer first-line option for mild pain during pregnancy. Pregnant women should discuss any planned use of topical salicylate or NSAID products with their obstetrician or midwife.
The standard Salonpas Pain Relieving Patch contains methyl salicylate (10%) and menthol (3%), producing a predominantly cooling counterirritant sensation through TRPM8 receptor activation. Salonpas Gel-Patch HOT contains methyl salicylate and menthol at somewhat different concentrations but additionally includes capsicum extract (capsaicinoids), which activates TRPV1 heat-sensing receptors to produce a warming sensation. Some users prefer the HOT variant for chronic muscular tension or cold-weather stiffness, while others find the cooling action of the standard patch more soothing for acute injuries and sports-related pain. HOT variants are generally not suitable for people with sensitive skin, should not be combined with external heat, and can cause more intense burning sensations. Always choose the formulation that matches your comfort preference and the type of pain you are treating.
References
This article is based on current international medical guidelines, regulatory documents, and peer-reviewed research. All sources meet evidence level 1A standards.
- U.S. Food and Drug Administration (FDA). Salonpas Pain Relieving Patch — OTC Drug Approval, New Drug Application (NDA) 21-929. Hisamitsu Pharmaceutical; approved January 2008. Regulatory review documents and full prescribing information.
- Derry S, Wiffen PJ, Kalso EA, et al. Topical analgesics for acute and chronic pain in adults — an overview of Cochrane Reviews. Cochrane Database of Systematic Reviews. 2017;5:CD008609. doi:10.1002/14651858.CD008609.pub2
- Higashi Y, Kiuchi T, Furuta K. Efficacy and safety profile of a topical methyl salicylate and menthol patch in adult patients with mild to moderate muscle strain: a randomized, double-blind, parallel-group, placebo-controlled, multicenter study. Clinical Therapeutics. 2010;32(1):34-43. doi:10.1016/j.clinthera.2010.01.016
- Mason L, Moore RA, Edwards JE, McQuay HJ, Derry S, Wiffen PJ. Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. BMJ. 2004;328(7446):995. doi:10.1136/bmj.38040.607141.EE
- World Health Organization (WHO). WHO Guidelines on the Pharmacological Treatment of Persisting Pain in Children with Medical Illnesses. Geneva: WHO; 2022. Discussion of salicylate use in pediatric pain management.
- Chan TY. Potential dangers from topical preparations containing methyl salicylate. Human & Experimental Toxicology. 1996;15(9):747-750. doi:10.1177/096032719601500905
- Bell AJ, Duggin G. Acute methyl salicylate toxicity complicating herbal skin treatment for psoriasis. Emergency Medicine (Fremantle). 2002;14(2):188-190. doi:10.1046/j.1442-2026.2002.00316.x
- Le Bars D, Gozariu M, Cadden SW. Animal models of nociception and the pharmacology of counterirritant analgesics: the role of TRP channels. Pharmacological Reviews. 2001;53(4):597-652. Foundational review of TRPM8 and TRPV1 mechanisms underlying topical menthol and capsaicin products.
- Joint Formulary Committee. British National Formulary (BNF) — Topical Rubefacients and Counter-Irritants. London: BMJ Group and Pharmaceutical Press; 2024. Evidence-based prescribing reference.
- American Association of Poison Control Centers (AAPCC). Annual Report of the National Poison Data System (NPDS): Salicylate Exposures and Methyl Salicylate Toxicity Surveillance. Clinical Toxicology. 2023. Epidemiologic data on topical salicylate-related adverse events.
- Joss JD, LeBlond RF. Potentiation of warfarin anticoagulation associated with topical methyl salicylate. Annals of Pharmacotherapy. 2000;34(6):729-733. doi:10.1345/aph.19303
- European Medicines Agency (EMA). Committee for Medicinal Products for Human Use: Review of Topical NSAIDs and Salicylates. EMA/CHMP; 2023. Overview of regulatory guidance on topical analgesics in the European Union.
Editorial Team
This article has been written and reviewed by the iMedic medical editorial team according to our strict editorial standards. Our team consists of licensed physicians, pharmacists, and medical researchers with expertise in clinical pharmacology, pain management, and musculoskeletal medicine.
Content developed by iMedic's medical writing team based on current international guidelines (FDA OTC drug label, WHO, EMA, BNF) and peer-reviewed pharmacological and clinical research on topical analgesics.
Independently reviewed and fact-checked by the iMedic Medical Review Board, comprising board-certified specialists in clinical pharmacology, pain medicine, and dermatology.
All medical claims are supported by Level 1A evidence (systematic reviews, meta-analyses, and randomized controlled trials) following the GRADE evidence framework.
iMedic receives no commercial funding from pharmaceutical companies, including the manufacturer of Salonpas. All content is editorially independent with no conflicts of interest.